Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Superior vena cava syndrome.

Janice D Nunnelee1

  • 1Chamberlain College of Nursing, St Louis, Missouri, USA. jannunn@sbcglobal.net

Journal of Vascular Nursing : Official Publication of the Society for Peripheral Vascular Nursing
|February 28, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Review of an article: oral rivaroxaban for symptomatic venous thromboembolism. The EINSTEIN Investigators et al. N Engl J Med 2010; 363(26):2499-2510.

Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing·2011
Same author

Review of an article: Self-management for oral anticoagulation (2009). Garcia-Alamino JM, Martin JLR, Subirana M & Gich I. Cochrane, Database of Systematic Reviews 4(CD003839). DOI 10.1002/14651858.CD003839.

Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing·2010
Same author

Review of an Article: Dabigatran versus warfarin in the treatment of acute venous thromboembolism (2009). Schulman S, Kearon C, Kakkar A, et al., N Engl J Med 361;2342-2352.

Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing·2010
Same author

Review of an Article: The international Warfarin Pharmacogenetics Consortium (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. NEJM 360 (8): 753-64.

Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing·2009
Same author

Review of an article: Canonico M, Plu-Bureau G, Lowe G, Scarabin P. (2008). Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. British Medical Journal 10(336):1227-1231.

Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing·2009
Same author

Review of an article: nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease and death in men and women. Nordestgaard B, Benn M, Schnohr P, Tybjaerg-Hansen A. JAMA 2007;298:299-308.

Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing·2008

Superior vena cava syndrome (SVCS) results from superior vena cava compression, often caused by lung cancer or thrombosis. Treatment depends on the cause, ranging from medication and radiation to surgical interventions like stenting.

Area of Science:

  • Medical Sciences
  • Cardiovascular Medicine
  • Oncology

Background:

  • Superior vena cava syndrome (SVCS) presents with symptoms due to compression of the superior vena cava.
  • Historically linked to infections like tuberculosis, current causes predominantly include malignancies and thrombotic events.
  • Lung adenocarcinoma is the most frequent cause, with increasing thrombotic origins due to medical devices.

Purpose of the Study:

  • To summarize the causes, symptoms, clinical findings, and treatment modalities for superior vena cava syndrome.
  • To highlight the evolving etiology of SVCS, emphasizing the role of cancer and iatrogenic thrombosis.

Main Methods:

  • Literature review of superior vena cava syndrome.
  • Analysis of etiological factors, clinical manifestations, and therapeutic strategies.

Related Experiment Videos

Main Results:

  • Common symptoms include head fullness, dyspnea, and cough.
  • Clinical signs encompass facial/neck swelling, dilated superficial veins, flushing, cyanosis, respiratory distress, and neurological deficits.
  • Malignancy, particularly lung adenocarcinoma, is the leading cause, followed by increasing thrombotic events linked to central venous catheters and pacemakers.

Conclusions:

  • Treatment strategies for SVCS are tailored to the underlying cause, including thrombolysis, anticoagulation, chemotherapy, radiation, angioplasty, stenting, or bypass surgery.
  • Prompt diagnosis and cause-specific management are crucial for favorable outcomes in patients with SVCS.